• ReNerve Limited has secured marketing approval for its NervAlign® Nerve Cuff in Indonesia
• Indonesia is a significant market for nerve repair solutions due to its large population and high trauma burden
• This approval expands ReNerve's presence in the Asia-Pacific region

ReNerve Limited (ASX: RNV), an Australian biotechnology company specializing in peripheral nerve injury repair, has announced that it has received marketing approval for its NervAlign® Nerve Cuff in Indonesia. This approval marks a significant milestone in ReNerve's Asia-Pacific expansion strategy. Indonesia, the world's fourth most populous nation with over 280 million people, represents a substantial opportunity for nerve repair solutions due to its high burden of trauma-related nerve injuries. The Asia-Pacific nerve repair market is estimated to be worth around USD $100 million in 2026, with Indonesia being a strategically significant market. The NervAlign® Nerve Cuff, which has already demonstrated remarkable clinical success in the United States, is expected to bring significant benefits to Indonesian clinicians and patients.